What they say:
A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: USF1 (Upstream Transcription Factor 1) inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3
Significance of the study:
USF1 (Upstream Transcription Factor 1), by increasing the expression of its target gene, it may decrease the expression of Notch3 (Fig.1).
Figure 1. Mechanistic insights into how USF-1 inhibits the development of pulmonary hypertension via up regulation of its target gene
Thus, pharmacological formulations encompassing “USF1 activators or its analogues, either alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension.
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Undisclosed mechanistic information: How USF1 decreases the expression of Notch3
Amount: $100#
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at info@genomediscovery.org
# Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Molecular therapy for pulmonary arterial hypertension: USF1 (Upstream Transcription Factor 1) inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 9/June/2017, 11.58 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, drop us a line at info@genomediscovery.org